Profile data is unavailable for this security.
About the company
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.
- Revenue in USD (TTM)0.00
- Net income in USD-8.54m
- Incorporated2004
- Employees12.00
- LocationKiora Pharmaceuticals Inc169 SAXONY RD., SUITE 212ENCINITAS 92024United StatesUSA
- Phone+1 (302) 636-5400
- Fax+1 (302) 636-5454
- Websitehttps://kiorapharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aptevo Therapeutics Inc | 0.00 | -27.95m | 7.07m | 37.00 | -- | 0.3128 | -- | -- | -306,220.00 | -306,220.00 | 0.00 | 22.67 | 0.00 | -- | -- | 0.00 | -125.64 | -47.17 | -172.77 | -82.66 | -- | -- | -- | -487.43 | -- | -- | 0.00 | -- | -- | -- | -29.38 | -- | -- | -- |
| Theriva Biologics Inc | 0.00 | -26.19m | 7.09m | 22.00 | -- | 0.3039 | -- | -- | -5.53 | -5.53 | 0.00 | 0.6539 | 0.00 | -- | -- | 0.00 | -73.83 | -37.94 | -99.55 | -42.02 | -- | -- | -- | -- | -- | -- | 0.2025 | -- | -- | -- | -39.81 | -- | -- | -- |
| Pharmacyte Biotech Inc | 0.00 | -8.98m | 7.14m | 2.00 | -- | 0.1343 | -- | -- | -1.32 | -1.32 | 0.00 | 5.38 | 0.00 | -- | -- | 0.00 | -12.74 | 7.21 | -13.51 | 7.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 235.53 | -- | -- | -- |
| Intelligent Bio Solutions Inc | 3.58m | -11.29m | 7.15m | 16.00 | -- | 0.4979 | -- | 2.00 | -15.13 | -15.13 | 4.65 | 8.96 | 0.272 | 2.98 | 9.91 | 223,832.50 | -86.08 | -73.55 | -132.01 | -123.30 | 46.21 | -- | -316.50 | -476.22 | 2.26 | -241.14 | 0.0012 | -- | -1.90 | 74.49 | -4.06 | -- | -- | -- |
| Aspire Biopharma Holdings Inc | 1.94k | -28.70m | 7.29m | -- | -- | -- | -- | 3,755.16 | -65.96 | -65.96 | 0.0022 | -9.26 | 0.0004 | -- | -- | -- | -633.21 | -- | -- | -- | 45.36 | -- | -1,479,598.00 | -- | 0.1708 | -6.20 | -- | -- | -- | -- | -380.85 | -- | -- | -- |
| Calcimedica Inc | 0.00 | -23.06m | 7.30m | 14.00 | -- | -- | -- | -- | -1.60 | -1.60 | 0.00 | -0.0188 | 0.00 | -- | -- | 0.00 | -148.18 | -58.12 | -194.91 | -64.99 | -- | -- | -- | -- | -- | -- | 1.03 | -- | -- | -- | 60.12 | -- | -57.90 | -- |
| TRON Group Inc | 1.01m | -549.47k | 7.38m | 50.00 | -- | -- | -- | 7.31 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| Alaunos Therapeutics Inc | 6.00k | -4.03m | 7.41m | 1.00 | -- | 2.61 | -- | 1,234.95 | -2.29 | -2.29 | 0.0034 | 1.27 | 0.0017 | -- | -- | 6,000.00 | -110.67 | -63.80 | -145.65 | -77.93 | -- | -- | -67,083.34 | -7,084.74 | -- | -- | 0.00 | -- | 100.00 | -- | 86.68 | -- | -- | -- |
| Kiora Pharmaceuticals Inc | 0.00 | -8.54m | 7.58m | 12.00 | -- | 0.3156 | -- | -- | -2.05 | -2.05 | 0.00 | 6.53 | 0.00 | -- | -- | 0.00 | -24.99 | -48.77 | -27.44 | -56.18 | -- | -- | -- | -276.73 | -- | -- | 0.00 | -- | -- | 42.93 | 127.56 | -- | -- | -- |
| Synlogic Inc | 0.00 | -3.23m | 7.60m | 1.00 | -- | 0.7365 | -- | -- | -0.2625 | -0.2625 | 0.00 | 0.8826 | 0.00 | -- | -- | 0.00 | -17.30 | -44.41 | -27.54 | -50.06 | -- | -- | -- | -3,944.49 | -- | -- | 0.00 | -- | -99.76 | -67.55 | 61.88 | -- | -59.28 | -- |
| Alzamend Neuro Inc | 0.00 | -6.47m | 7.65m | 4.00 | -- | 1.75 | -- | -- | -5.71 | -5.71 | 0.00 | 1.15 | 0.00 | -- | -- | 0.00 | -116.49 | -171.97 | -144.76 | -256.71 | -- | -- | -- | -- | -- | -766.93 | 0.00 | -- | -- | -- | 48.68 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -10.85m | 7.84m | 27.00 | -- | -- | -- | -- | -1.50 | -1.50 | 0.00 | -0.6973 | 0.00 | -- | -- | 0.00 | -637.06 | -112.30 | -- | -219.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 32.39 | -- | -- | -- |
| Curative Biotechnology Inc | 0.00 | -6.02m | 7.94m | 4.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0018 | 0.00 | -- | -- | 0.00 | -339.98 | -- | -- | -- | -- | -- | -- | -- | -- | -5.51 | -- | -- | -- | -- | -302.92 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Adar1 Capital Management LLCas of 31 Dec 2025 | 167.94k | 4.57% |
| Stonepine Capital Management LLCas of 31 Dec 2025 | 131.14k | 3.57% |
| DRW Securities LLCas of 31 Dec 2025 | 110.28k | 3.00% |
| Nantahala Capital Management LLCas of 31 Dec 2025 | 106.16k | 2.89% |
| Alyeska Investment Group LPas of 31 Dec 2025 | 76.90k | 2.09% |
| Citadel Securities LLCas of 31 Dec 2025 | 22.38k | 0.61% |
| Geode Capital Management LLCas of 31 Dec 2025 | 22.01k | 0.60% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 21.20k | 0.58% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 19.86k | 0.54% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 13.03k | 0.35% |
